Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 82

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 82
---
 our CROs or CMOs, may knowingly or inadvertently make use of social media in a manner that may give rise to liability, lead to
the loss of trade secrets or other intellectual property or result in public exposure of personal information of our employees, clinical
trial patients, customers and others or information regarding our product candidates or clinical trials. Any of these events could have
a material adverse effect on our business, prospects, operating results and financial condition and could adversely affect the price of
our common shares.

Risks Related to our Intellectual Property

We depend on obtaining certain patents and
protecting our proprietary rights.

Our success will depend, in
part, on our ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of third
parties or having third parties circumvent our rights. We have filed and are actively pursuing a patent application for our product candidates.
The patent positions of biotechnology, biopharmaceutical and pharmaceutical companies can be highly uncertain and involve complex legal
and factual questions. Thus, there can be no assurance that our patent application will result in the issuance of a patent, that we will
develop additional proprietary products that are patentable, that any patents issued to us will provide us with any competitive advantages
or will not be challenged by any third parties, that the patents of others will not impede our ability to do business or that third parties
will not be able to circumvent our patents. Furthermore, there can be no assurance that others will not independently develop similar
products, duplicate any of our products not under patent protection, or, if patents are issued to us, design around the patented products
we developed or will develop.

We may be required to obtain
licenses from third parties to avoid infringing patents or other proprietary rights. No assurance can be given that any licenses required
under any such patents or proprietary rights would be made available, if at all, on terms we find acceptable. If we do not obtain such
licenses, we could encounter delays in the introduction of products or could find that the development, manufacture or sale of products
requiring such licenses could be prohibited.

48

A number of pharmaceutical,
biopharmaceutical and biotechnology companies and research and academic institutions have developed technologies, filed patent applications
or received patents on various technologies that may be related to or affect our business. Some of these technologies, applications or
patents may conflict with our technologies or patent applications. Such conflict could limit the scope of the patents, if any